0.2965
price up icon3.24%   0.0093
after-market After Hours: .30 0.0035 +1.18%
loading
Cel-Sci Corp. stock is traded at $0.2965, with a volume of 1.21M. It is up +3.24% in the last 24 hours and up +11.34% over the past month. CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The company's Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.
See More
Previous Close:
$0.2872
Open:
$0.2928
24h Volume:
1.21M
Relative Volume:
0.84
Market Cap:
$21.43M
Revenue:
-
Net Income/Loss:
$-26.92M
P/E Ratio:
-0.5814
EPS:
-0.51
Net Cash Flow:
$-18.92M
1W Performance:
+16.37%
1M Performance:
+11.34%
6M Performance:
-67.23%
1Y Performance:
-79.69%
1-Day Range:
Value
$0.2852
$0.3099
1-Week Range:
Value
$0.2501
$0.3111
52-Week Range:
Value
$0.18
$2.39

Cel-Sci Corp. Stock (CVM) Company Profile

Name
Name
Cel-Sci Corp.
Name
Phone
703-506-9460
Name
Address
8229 Boone Boulevard, Suite 802, Vienna, VA
Name
Employee
0
Name
Twitter
@CelSciCorp
Name
Next Earnings Date
2025-02-18
Name
Latest SEC Filings
Name
CVM's Discussions on Twitter

Compare CVM with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CVM
Cel-Sci Corp.
0.2965 21.43M 0 -26.92M -18.92M -0.51
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.47 125.74B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
599.76 61.57B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
600.51 36.40B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
242.61 30.36B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
256.16 24.89B 3.81B -644.79M -669.77M -6.24

Cel-Sci Corp. Stock (CVM) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-13-20 Initiated H.C. Wainwright Buy
Mar-02-15 Initiated Dawson James Buy

Cel-Sci Corp. Stock (CVM) Latest News

pulisher
Apr 24, 2025

US biotech seeks Saudi approval for cancer treatment - Arabian Gulf Business Insight | AGBI

Apr 24, 2025
pulisher
Apr 23, 2025

CEL-SCI to seek Saudi approval for cancer treatment - Investing.com

Apr 23, 2025
pulisher
Apr 23, 2025

CEL-SCI Corp To File For Regulatory Approval Of Multikine In Saudi Arabia - marketscreener.com

Apr 23, 2025
pulisher
Apr 23, 2025

CEL-SCI to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market - Yahoo Finance

Apr 23, 2025
pulisher
Apr 23, 2025

Market Momentum Report: Cel-Sci Corp (CVM)’s Positive Close at 0.27 - DWinneX

Apr 23, 2025
pulisher
Apr 23, 2025

Its Stock Has Paid Off Big Time For Cel-Sci Corp - Sete News

Apr 23, 2025
pulisher
Apr 22, 2025

An Analysis of Cel-Sci Corp (CVM)’s Potential Price Growth - knoxdaily.com

Apr 22, 2025
pulisher
Apr 22, 2025

Parsons Corp [PSN] Investment Appeal on the Rise - knoxdaily.com

Apr 22, 2025
pulisher
Apr 22, 2025

Cel-Sci Corp (CVM) presents a great opportunity, but the stock is slightly overvalued - uspostnews.com

Apr 22, 2025
pulisher
Apr 22, 2025

StockNews.com Initiates Coverage on CEL-SCI (NYSE:CVM) - Defense World

Apr 22, 2025
pulisher
Apr 11, 2025

CEL-SCI's Multikine (CVM) Shows Promising Survival Rates in Head and Neck Cancer Study - GuruFocus

Apr 11, 2025
pulisher
Apr 11, 2025

12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga

Apr 11, 2025
pulisher
Apr 09, 2025

CVM stock touches 52-week low at $0.18 amid sharp annual decline - Investing.com Australia

Apr 09, 2025
pulisher
Apr 09, 2025

CVM stock touches 52-week low at $0.18 amid sharp annual decline By Investing.com - Investing.com South Africa

Apr 09, 2025
pulisher
Apr 08, 2025

Breakthrough Cancer Study: New Data Shows 306% Survival Boost for Multikine Treatment - Stock Titan

Apr 08, 2025
pulisher
Apr 06, 2025

CEL-SCI (NYSE:CVM) Now Covered by StockNews.com - Defense World

Apr 06, 2025
pulisher
Mar 31, 2025

CVM stock touches 52-week low at $0.23 amid sharp annual decline By Investing.com - Investing.com South Africa

Mar 31, 2025
pulisher
Mar 31, 2025

CVM stock touches 52-week low at $0.23 amid sharp annual decline - Investing.com Australia

Mar 31, 2025
pulisher
Mar 29, 2025

CEL-SCI (NYSE:CVM) Earns Sell Rating from Analysts at StockNews.com - Defense World

Mar 29, 2025
pulisher
Mar 24, 2025

Breakthrough: New Cancer Drug Delivers 95% Quality of Life Improvement for Head & Neck Patients - Stock Titan

Mar 24, 2025
pulisher
Mar 21, 2025

CVM stock touches 52-week low at $0.26 amid sharp annual decline - Investing.com Australia

Mar 21, 2025
pulisher
Mar 21, 2025

CVM stock touches 52-week low at $0.26 amid sharp annual decline By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 21, 2025

Cel-Sci Corp (CVM) Volatility Hits 12.01%: What Good Investors Need To Be Aware Of - Stocks Register

Mar 21, 2025
pulisher
Mar 18, 2025

CEL-SCI announces closing of $2.5 million offering -March 18, 2025 at 05:23 pm EDT - Marketscreener.com

Mar 18, 2025
pulisher
Mar 18, 2025

CEL-SCI Secures $2.5M Funding: Major Push for FDA-Designated Cancer Immunotherapy - StockTitan

Mar 18, 2025
pulisher
Mar 18, 2025

Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 18, 2025
pulisher
Mar 17, 2025

CEL-SCI Secures Critical Funding for FDA-Approved Head & Neck Cancer Treatment Study - StockTitan

Mar 17, 2025
pulisher
Mar 17, 2025

CEL-SCI advances in head and neck cancer treatment study - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Mar 17, 2025
pulisher
Mar 17, 2025

CEL-SCI advances in head and neck cancer treatment study By Investing.com - Investing.com UK

Mar 17, 2025
pulisher
Mar 17, 2025

CEL-SCI’s Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine - Yahoo Finance

Mar 17, 2025
pulisher
Mar 15, 2025

Cel-Sci Corp (CVM) Recovers 5.85% From Low: Are We There Yet? - Stocks Register

Mar 15, 2025
pulisher
Mar 14, 2025

Major Breakthrough: JAMA Study Shows Multikine Triples Survival Rates in Head and Neck Cancer - StockTitan

Mar 14, 2025
pulisher
Mar 13, 2025

CEL-SCI (NYSE:CVM) Coverage Initiated at StockNews.com - Defense World

Mar 13, 2025
pulisher
Mar 10, 2025

CVM stock touches 52-week low at $0.31 amid sharp annual decline - Investing.com Australia

Mar 10, 2025
pulisher
Mar 10, 2025

CVM stock touches 52-week low at $0.31 amid sharp annual decline By Investing.com - Investing.com South Africa

Mar 10, 2025
pulisher
Mar 06, 2025

CVMCEL-SCI Corp Latest Stock News & Market Updates - Stock Titan

Mar 06, 2025
pulisher
Mar 05, 2025

4 Biotech Stocks To Watch: CVM, NKGN, NBIO, IMUX - DRP Journal

Mar 05, 2025
pulisher
Mar 05, 2025

CEL-SCI Announces That NYSE MKT Granted an Extension to Regain Compliance - AOL

Mar 05, 2025
pulisher
Feb 28, 2025

CVM Stock Hits 52-Week Low at $0.33 Amid Steep Annual Decline - Investing.com Australia

Feb 28, 2025
pulisher
Feb 27, 2025

CVM Stock Hits 52-Week Low at $0.33 Amid Steep Annual Decline By Investing.com - Investing.com South Africa

Feb 27, 2025
pulisher
Feb 20, 2025

CEL-SCI advances Multikine study for head and neck cancer - Investing.com

Feb 20, 2025
pulisher
Feb 20, 2025

CEL-SCI advances Multikine study for head and neck cancer By Investing.com - Investing.com UK

Feb 20, 2025
pulisher
Feb 20, 2025

CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial -February 20, 2025 at 08:06 am EST - Marketscreener.com

Feb 20, 2025
pulisher
Feb 20, 2025

CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial - Yahoo Finance

Feb 20, 2025
pulisher
Feb 20, 2025

Can This Cancer Drug Triple Patient Survival Rates? New Trial Holds Answer - Stock Titan

Feb 20, 2025
pulisher
Feb 19, 2025

CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks - BioSpace

Feb 19, 2025
pulisher
Feb 18, 2025

StockNews.com Begins Coverage on CEL-SCI (NYSE:CVM) - Armenian Reporter

Feb 18, 2025
pulisher
Feb 17, 2025

CEL-SCI (NYSE:CVM) Now Covered by Analysts at StockNews.com - Defense World

Feb 17, 2025
pulisher
Feb 15, 2025

Cel-Sci: Fiscal Q1 Earnings Snapshot - mySA

Feb 15, 2025

Cel-Sci Corp. Stock (CVM) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.54
price up icon 2.04%
$68.96
price down icon 2.60%
$32.03
price up icon 1.07%
$36.70
price up icon 10.44%
$120.54
price up icon 4.97%
biotechnology ONC
$256.16
price up icon 2.82%
Cap:     |  Volume (24h):